Abstract:Introduction: Ki67 value and its variation before and after neoadjuvant chemotherapy are commonly tested in relation to breast cancer patient prognosis. This study aims to quantify the extent of changes in Ki67 proliferation pre- and post-neoadjuvant chemotherapy, confirm an optimal cut-off point, and evaluate its potential value for predicting survival outcomes in patients with different molecular subtypes of breast cancer. Methods: This retrospective real-world study recruited 828 patients at the Department of Breast Surgery of the First Affiliated Hospital of China Medical University and the Cancer Hospital of China Medical University from Jan 2014 to Nov 2020. Patient demographic features and disease pathology characteristics were recorded, and biomarkers were verified through immunohistochemistry. Various statistical methods were used to validate the relationships between different characteristics and survival outcomes irrespective of disease-free and overall survival. Results: Among 828 patients, statistically significant effects between pathological complete response and survival outcome were found in both HER2-enriched and triple-negative breast cancer ( p < 0.05) but not in Luminal breast cancer ( p > 0.05). Evident decrease of Ki67 was confirmed after neoadjuvant chemotherapy. To quantify the extent of Ki67 changes between pre- and post-NAC timepoints, we adopted a computational equation termed ΔKi67% for research. We found the optimal cut-off value to be “ ΔKi67% = −63%” via the operating characteristic curve, defining ΔKi67% ≤ −63% as positive status and ΔKi67% > −63% as negative status. Patients with positive ΔKi67% status were 37.1% of the entire cohort. Additionally, 4.7, 39.9, 34.5 and 39.6% of patients with Luminal A, Luminal B, HER2-enriched and triple negative breast cancer were also validated with positive ΔKi67% status. The statistically significant differences between ΔKi67% status and prognostic outcomes were confirmed by univariate and multivariate analysis in Luminal B (univariate and multivariate analysis: p < 0.05) and triple negative breast cancer (univariate and multivariate analysis: p < 0.05). We proved ΔKi67% as a statistically significant independent prognostic factor irrespective of disease-free or overall survival among patients with Luminal B and triple-negative breast cancer. Conclusions: ΔKi67% can aid in predicting patient prognostic outcome, provide a measurement of NAC efficacy, and assist in further clinical decisions, especially for patients with Luminal B breast cancer.

Relationship Between Ki67 and Response to Neoadjuvant Chemotherapy in HR Negative Breast Cancer Patients

Effects of Core Needle Biopsy and Subsequent Neoadjuvant Chemotherapy on Molecular Alterations and Outcome in Breast Cancer

HER2 Protein Expression Level is Positively Associated with the Efficacy of Neoadjuvant Systemic Therapy in HER2-positive Breast Cancer

Expression of ER, PR, HER-2, Ki-67 Before and after Neoadjuvant Chemotherapy and the Relation Between Their Expression and the Curative Effects of Neoadjuvant Chemotherapy in Breast Cancer

Clinical research of utilizing Ki67 in predicting the effect of neoadjuvant chemotherapy on breast cancer

Ki?67 Expression and Its Effect on Response to Neo?adjuvant Chemotherapy in Invasive Breast Cancer

[Relationship Between Ki67 Expression and Tumor Response to Neoadjuvant Chemotherapy with Anthracyclines Plus Taxanes in Breast Cancer].

Abstract P1-08-05: the Prognostic Significance of Ki-67 Expression Before and after Neoadjuvant Anthracycline-Taxane-based Chemotherapy in Different Biological Breast Cancer Phenotypes

Assessment of the predictive role of pretreatment Ki-67 and Ki-67 changes in breast cancer patients receiving neoadjuvant chemotherapy according to the molecular classification: a retrospective study of 1010 patients

Association Between Hormone Receptors and Response to Neoadjuvant Anthracycline-Based Chemotherapy in Breast Cancer Patients

Association Between the HER2 Protein Expression Level and the Efficacy of Neoadjuvant Chemotherapy in HER2-Positive Breast Cancer

The predictive value of Ki-67 before neoadjuvant chemotherapy for breast cancer: a systematic review and meta-analysis

The Predictive Value of Ki-67 Before Neoadjuvant Chemotherapy for Breast Cancer: a Systematic Review and Meta-Analysis.

Assessment of the Predictive Role of Ki-67 in Breast Cancer Patients' Responses to Neoadjuvant Chemotherapy

The Effect of Ki-67 Expression on the Clinical Efficacy of Neoadjuvant Chemotherapy with AC-T Chemo-Therapy for Locally Advanced Breast Cancer

Relationship between the expression of Ki-67 and pathological complete response in triple-negative breast cancer before neoadjuvant chemotherapy:A Meta-analysis

Quantification of Ki67 Change as a Valid Prognostic Indicator of Luminal B Type Breast Cancer After Neoadjuvant Therapy

Decrease in the Ki67 Index During Neoadjuvant Chemotherapy Predicts Favorable Relapse-Free Survival in Patients with Locally Advanced Breast Cancer

[Analysis of associations between molecular subtypes and responses to neoadjuvant chemotherapy in primary breast cancer patients]

Survivin, Ki-67 and Tumor Grade As Predictors of Response to Docetaxel-Based Neoadjuvant Chemotherapy in Locally Advanced Breast Cancer.

The clinical significance of Ki-67 as a marker of prognostic value and chemosensitivity prediction in hormone-receptor-positive breast cancer: a meta-analysis of the published literature.